Skip to main content
Premium Trial:

Request an Annual Quote

Where Are They Now?: Jan 1, 2003

Premium

Last January, TIGR head Claire Fraser graced the cover of Genome Technology. Inside, Fraser talked about how the institute had evolved over its decade-long existence into a microbial sequencing powerhouse. Since then, hubby Craig Venter started three new institutes to go along with the TIGR family and announced plans to turn TIGR’s sequencing facility into a high-quality closure workshop. (See last month’s GT for more on Venter’s vision.)

Also in last year’s issue: execs from Genaissance, Orchid, and Variagenics shared their know-how on setting up a large-scale SNP shop. Since then, though, the SNP scene has gotten significantly smaller. Genaissance cut 20 percent of its staff and appointed a new CEO, Orchid put its SNP instrument biz on the block, and Hyseq merged with the struggling Variagenics for its cash (see p. 19).

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.